<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:749.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">Critical Care Medicine </span></p>
<p style="top:751.4pt;left:423.4pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt"> </span></p>
<p style="top:749.8pt;left:532.8pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">413</span></b></p>
<p style="top:248.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Objective:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> Inhaled anticoagulation regimens are increasingly being </span></p>
<p style="top:260.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">used to manage smoke inhalation&#x2013;associated acute lung injury. </span></p>
<p style="top:272.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">We systematically reviewed published and unpublished preclini-</span></p>
<p style="top:284.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">cal and clinical trial data to elucidate the effects of these regimens </span></p>
<p style="top:296.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">on lung injury severity, airway obstruction, ventilation, oxygenation, </span></p>
<p style="top:308.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">pulmonary infections, bleeding complications, and survival.</span></p>
<p style="top:320.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Data Sources:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> PubMed, Scopus, EMBASE, and Web of Science </span></p>
<p style="top:332.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">were searched to identify relevant published studies. Relevant </span></p>
<p style="top:344.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">unpublished studies were identified by searching the Australian </span></p>
<p style="top:356.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">and New Zealand Clinical Trials Registry, World Health Organi-</span></p>
<p style="top:368.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">zation International Clinical Trials Registry Platform, Cochrane </span></p>
<p style="top:380.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Library, ClinicalTrials.gov, MINDCULL.com, Current Controlled </span></p>
<p style="top:392.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Trials, and Google.</span></p>
<p style="top:404.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Study Selection:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> Inclusion criteria were any preclinical or clinical </span></p>
<p style="top:416.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">study in which 1) animals or subjects experienced smoke inhala-</span></p>
<p style="top:428.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">tion exposure, 2) they were treated with nebulized or aerosolized </span></p>
<p style="top:440.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">anticoagulation regimens, including heparin, heparinoids, anti-</span></p>
<p style="top:452.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">thrombins, or fibrinolytics (e.g., tissue plasminogen activator), 3) </span></p>
<p style="top:464.0pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">a control and/or sham group was described for preclinical stud-</span></p>
<p style="top:248.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">ies, and 4) a concurrent or historical control group described for </span></p>
<p style="top:260.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">clinical studies. Exclusion criteria were 1) the absence of a group </span></p>
<p style="top:272.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">treated with a nebulized or aerosolized anticoagulation regimen, </span></p>
<p style="top:284.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">2) the absence of a control or sham group, and 3) case reports.</span></p>
<p style="top:296.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Data Extraction:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> Ninety-nine potentially relevant references were </span></p>
<p style="top:308.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">identified. Twenty-seven references met inclusion criteria includ-</span></p>
<p style="top:320.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">ing 19 preclinical references reporting 18 studies and eight clini-</span></p>
<p style="top:332.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">cal references reporting five clinical studies.</span></p>
<p style="top:344.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Data Synthesis:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> A systematic review of the literature is provided. </span></p>
<p style="top:356.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Both clinical and methodological diversity precluded combining </span></p>
<p style="top:368.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">these studies in a meta-analysis.</span></p>
<p style="top:380.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Conclusions:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> The high mortality associated with smoke inhalation&#x2013;</span></p>
<p style="top:392.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">associated acute lung injury results from airway damage, mucosal </span></p>
<p style="top:404.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">dysfunction, neutrophil infiltration, airway coagulopathy with cast </span></p>
<p style="top:416.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">formation, ventilation-perfusion mismatching with shunt, and baro-</span></p>
<p style="top:428.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">trauma. Inhaled anticoagulation regimens in both preclinical and </span></p>
<p style="top:440.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">clinical studies improve survival and decrease morbidity without </span></p>
<p style="top:452.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">altering systemic markers of clotting and anticoagulation. In some </span></p>
<p style="top:464.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">preclinical and clinical studies, inhaled anticoagulants were asso-</span></p>
<p style="top:476.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">ciated with a favorable effect on survival. This approach appears </span></p>
<p style="top:488.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">sufficiently promising to merit a well-designed prospective study </span></p>
<p style="top:500.0pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">to validate its use in patients with severe smoke inhalation&#x2013;associ-</span></p>
<p style="top:511.9pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">ated acute lung injury requiring mechanical ventilation. (</span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Crit Care </span></i></p>
<p style="top:523.9pt;left:300.0pt;line-height:9.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> 2014; 42:413&#x2013;419)</span></p>
<p style="top:535.9pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Key Words:</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> acute lung injury; anticoagulants; antithrombins; </span></p>
<p style="top:547.9pt;left:300.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">fibrinolytic agents; heparin; smoke inhalation injury</span></p>
<p style="top:587.4pt;left:300.0pt;line-height:46.9pt"><span style="font-family:Minion,serif;font-size:46.9pt;color:#939597">I</span></p>
<p style="top:593.0pt;left:315.8pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">n the United States, more than 450,000 burn injuries occur </span></p>
<p style="top:605.0pt;left:315.8pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">annually (1). Smoke inhalation&#x2013;associated acute lung </span></p>
<p style="top:617.0pt;left:315.8pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">injury (SI-ALI) constitutes a major cause of morbidity </span></p>
<p style="top:629.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">and mortality in victims of fire tragedies, affecting nearly 1.5&#x2013;</span></p>
<p style="top:641.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">19.5% of burn patients worldwide (1.5% Israel, 8% China, and </span></p>
<p style="top:653.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">19.5% United States) (2&#x2013;4). The prevalence of SI-ALI is cor-</span></p>
<p style="top:665.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">related with a greater percent of burn surface area (BSA) (3); </span></p>
<p style="top:677.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">however, significant SI-ALI may exist in the absence of cutane-</span></p>
<p style="top:689.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ous burns. When combined with cutaneous burns, inhalation </span></p>
<p style="top:701.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">injury increases fluid requirements for resuscitation, the preva-</span></p>
<p style="top:713.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">lence of pulmonary complications, and the mortality rate (3, </span></p>
<p style="top:725.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">5&#x2013;8). In a retrospective analysis of 573 burn patients admitted </span></p>
<p style="top:489.5pt;left:37.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">*See also p. 474.</span></b></p>
<p style="top:501.5pt;left:37.0pt;line-height:4.7pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.7pt">1</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Department of Critical Care Medicine, Clinical Center, National Institutes </span></p>
<p style="top:510.5pt;left:40.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">of Health, Bethesda, MD.</span></p>
<p style="top:522.5pt;left:37.0pt;line-height:4.7pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.7pt">2</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Department of Internal Medicine, Division of Pulmonary, Allergy, and Criti-</span></p>
<p style="top:531.5pt;left:40.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">cal Care, University of Pittsburgh Medical Center, Pittsburgh, PA.</span></p>
<p style="top:543.5pt;left:37.0pt;line-height:4.7pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.7pt">3</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Department of Internal Medicine, Division of Pulmonary, Critical Care, </span></p>
<p style="top:552.5pt;left:40.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and Sleep Medicine, James A. Haley Veteran&#x2019;s Hospital and University of </span></p>
<p style="top:561.5pt;left:40.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">South Florida, Tampa, FL.</span></p>
<p style="top:573.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">All authors contributed to all stages of manuscript planning, research, </span></p>
<p style="top:582.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">preparation, and revision.</span></p>
<p style="top:594.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Supplemental digital content is available for this article. Direct URL cita-</span></p>
<p style="top:603.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">tions appear in the printed text and are provided in the HTML and PDF </span></p>
<p style="top:612.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">versions of this article on the journal&#x2019;s website (http://journals.lww.com/</span></p>
<p style="top:621.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">ccmjournal).</span></p>
<p style="top:633.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Supported, in part, by the Intramural Research Program of the Clinical </span></p>
<p style="top:642.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Center, National Institutes of Health, and the Veterans Administration </span></p>
<p style="top:651.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Hospital.</span></p>
<p style="top:663.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Dr. Elamin received support for travel from SuperDimension. Dr. Suffredini </span></p>
<p style="top:672.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">received support for article research from the National Institutes of Health. </span></p>
<p style="top:681.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Dr. Miller disclosed that he does not have any potential conflicts of interest.</span></p>
<p style="top:693.5pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">For information regarding this article, E-mail: andrew.miller3@nih.gov</span></p>
<p style="top:705.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Copyright &#xa9; 2013 by the Society of Critical Care Medicine and Lippincott </span></p>
<p style="top:714.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Williams &amp; Wilkins</span></p>
<p style="top:726.6pt;left:37.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">DOI: 10.1097/CCM.0b013e3182a645e5</span></b></p>
<p style="top:119.9pt;left:37.0pt;line-height:22.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:22.0pt">Inhaled Anticoagulation Regimens for the </span></p>
<p style="top:143.9pt;left:37.0pt;line-height:22.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:22.0pt">Treatment of Smoke Inhalation&#x2013;Associated Acute </span></p>
<p style="top:167.9pt;left:37.0pt;line-height:22.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:22.0pt">Lung Injury: A Systematic Review*</span></p>
<p style="top:203.9pt;left:61.0pt;line-height:12.0pt"><span style="font-family:Minion,serif;font-size:12.0pt;color:#6c6e70">Andrew C. Miller, MD</span><sup><span style="font-family:Minion,serif;font-size:7.0pt;color:#6c6e70">1,2</span></sup><span style="font-family:Minion,serif;font-size:12.0pt;color:#6c6e70">; Elamin M. Elamin, MD, MSc</span><sup><span style="font-family:Minion,serif;font-size:7.0pt;color:#6c6e70">3</span></sup><span style="font-family:Minion,serif;font-size:12.0pt;color:#6c6e70">; Anthony F. Suffredini, MD</span><sup><span style="font-family:Minion,serif;font-size:7.0pt;color:#6c6e70">1</span></sup></p>


<p style="top:34.8pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Miller et al</span></p>
<p style="top:749.0pt;left:37.0pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">414</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:750.7pt;left:85.0pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:749.8pt;left:413.3pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">February&#xfffd;2014&#xfffd;&#x2022;&#xfffd;Volume&#xfffd;42&#xfffd;&#x2022;&#xfffd;Number&#xfffd;2</span></p>
<p style="top:59.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">over a 4-year period to a regional burn center, patients with </span></p>
<p style="top:71.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">inhalation injury had a more than 70% prevalence of respi-</span></p>
<p style="top:83.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ratory failure (hypoxemia, multiple pulmonary infections, or </span></p>
<p style="top:95.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">prolonged ventilatory support) and a 20% prevalence of acute </span></p>
<p style="top:107.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">respiratory distress syndrome (9). The reported mortality </span></p>
<p style="top:119.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">associated with SI-ALI ranges from 11% to 80% (3, 4, 8&#x2013;11). </span></p>
<p style="top:131.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">The variability in mortality rates from different regions of the </span></p>
<p style="top:143.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">world and time periods likely reflects the heterogeneity of the </span></p>
<p style="top:155.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">patient populations due to age, comorbidities, severity of the </span></p>
<p style="top:167.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">primary and secondary injuries, and variations in therapy.</span></p>
<p style="top:179.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Several mechanisms have been identified in animal models </span></p>
<p style="top:191.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">and in human pathologic studies that contribute to the develop-</span></p>
<p style="top:203.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ment of SI-ALI. Smoke inhalation promotes airway damage and </span></p>
<p style="top:215.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">inflammation. Immediately following smoke inhalation, bron-</span></p>
<p style="top:227.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">chial blood flow increases up to 20-fold (12). Increased microvas-</span></p>
<p style="top:239.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">cular permeability and airway edema results in plasma exudation </span></p>
<p style="top:251.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">into the airway resulting in intra-airway coagulation and fibrin </span></p>
<p style="top:263.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">deposition. Cellular debris, mucin, and fibrin deposition admix </span></p>
<p style="top:275.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to form a fibrinocellular exudate or pseudomembranes that may </span></p>
<p style="top:287.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">develop into obstructive airway casts that promote significant </span></p>
<p style="top:299.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">mismatch in ventilation and perfusion (V/Q) (2, 13&#x2013;23). The </span></p>
<p style="top:311.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">V/Q mismatch is further worsened by increased perfusion to </span></p>
<p style="top:323.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">underventilated lung regions due to impaired hypoxic vasocon-</span></p>
<p style="top:335.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">striction driven in part by increased nitric oxide production (24, </span></p>
<p style="top:347.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">25). Furthermore, partially obstructed airways may result in air </span></p>
<p style="top:359.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">trapping and alveolar hyperinflation via a ball-valve mechanism </span></p>
<p style="top:371.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">that may promote distal airway and alveolar damage. These </span></p>
<p style="top:383.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">mechanisms may lead to impaired oxygenation and ventilation. </span></p>
<p style="top:395.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Although on mechanical ventilation this may result in elevated </span></p>
<p style="top:407.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">peak and plateau pressures, auto-peep, and patient-ventilator </span></p>
<p style="top:419.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">dyssynchrony, this may promote regional barotrauma in some </span></p>
<p style="top:431.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">lung segments while resulting in repetitive alveolar collapse and </span></p>
<p style="top:443.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">expansion injury. Additionally, casts may also occlude endotra-</span></p>
<p style="top:455.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">cheal and tracheostomy tubes necessitating emergent airway </span></p>
<p style="top:467.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">revision (26).</span></p>
<p style="top:479.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">SI-ALI is an important yet understudied clinical problem. </span></p>
<p style="top:491.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">The use of inhaled anticoagulation regimens is increasingly </span></p>
<p style="top:503.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">being used to manage SI-ALI with the goal of improving out-</span></p>
<p style="top:515.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">comes by decreasing airways fibrin deposition and obstruction </span></p>
<p style="top:527.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(27). However, the data detailing the efficacy of this approach </span></p>
<p style="top:539.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">are limited and to our knowledge has not been compiled into </span></p>
<p style="top:551.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">a comprehensive review. We conducted this review to sum-</span></p>
<p style="top:563.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">marize the complex body of literature on the topic, assess the </span></p>
<p style="top:575.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">consistency of results across trials, clarify the strengths and </span></p>
<p style="top:587.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">weakness of available studies, and document the need for fur-</span></p>
<p style="top:599.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ther prospective clinical investigation. We systematically review </span></p>
<p style="top:611.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">published and unpublished preclinical and clinical study data </span></p>
<p style="top:623.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to elucidate the effects of such regimens on lung injury sever-</span></p>
<p style="top:635.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ity, airway obstruction, ventilation, oxygenation, pulmonary </span></p>
<p style="top:647.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">infections, bleeding complications, and survival.</span></p>
<p style="top:675.8pt;left:37.0pt;line-height:11.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:11.0pt">METHODS</span></b></p>
<p style="top:688.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">A systematic search was performed to capture published and </span></p>
<p style="top:700.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">unpublished preclinical and clinical studies of nebulized anti-</span></p>
<p style="top:712.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">coagulation regimens as treatment for SI-ALI. PubMed, Sco-</span></p>
<p style="top:724.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">pus, EMBASE, and Web of Science were searched to identify </span></p>
<p style="top:59.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">relevant published studies. The search strategies were adapted </span></p>
<p style="top:71.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to accommodate the unique searching features of each data-</span></p>
<p style="top:83.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">base, including database-specific MESH and EMTREE con-</span></p>
<p style="top:95.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">trolled vocabulary terms. Searches were not limited by date, </span></p>
<p style="top:107.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">language, or publication status. See </span><b><span style="font-family:Minion,serif;font-size:10.0pt">Appendix 1</span></b><span style="font-family:Minion,serif;font-size:10.0pt"> (Supple-</span></p>
<p style="top:119.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">mental Digital Content 1, http://links.lww.com/CCM/A741) </span></p>
<p style="top:131.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">for detailed search strategies. The cited and citing references </span></p>
<p style="top:143.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of selected studies were also searched for additional relevant </span></p>
<p style="top:155.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">material.</span></p>
<p style="top:167.6pt;left:312.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">To minimize publication bias, relevant unpublished stud-</span></p>
<p style="top:179.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ies were identified by searching the Australian and New </span></p>
<p style="top:191.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Zealand Clinical Trials Registry, World Health Organization </span></p>
<p style="top:203.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">International Clinical Trials Registry Platform, Cochrane </span></p>
<p style="top:215.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Library, </span></p>
<p style="top:215.6pt;left:344.6pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ClinicalTrials.gov, </span></p>
<p style="top:215.6pt;left:429.1pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">MINDCULL.com, </span></p>
<p style="top:215.6pt;left:516.2pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Current </span></p>
<p style="top:227.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Controlled Trials, and Google.</span></p>
<p style="top:239.6pt;left:312.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Inclusion criteria were any preclinical or clinical study in </span></p>
<p style="top:251.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">which 1) animals or subjects experienced smoke inhalation </span></p>
<p style="top:263.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">exposure, 2) they were treated with nebulized or aerosolized </span></p>
<p style="top:275.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">anticoagulation regimens, including heparin, heparinoids, </span></p>
<p style="top:287.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">antithrombins (ATs), or fibrinolytics (e.g., tissue plasminogen </span></p>
<p style="top:299.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">activator, TPA), 3) a control and/or sham group was described </span></p>
<p style="top:311.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">for preclinical studies, and 4) a concurrent or historical control </span></p>
<p style="top:323.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">group described for clinical studies. Exclusion criteria were 1) </span></p>
<p style="top:335.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">the absence of a group treated with a nebulized or aerosolized </span></p>
<p style="top:347.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">anticoagulation regimen, 2) the absence of a control or sham </span></p>
<p style="top:359.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">group, and 3) case reports.</span></p>
<p style="top:388.8pt;left:300.0pt;line-height:11.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:11.0pt">RESULTS</span></b></p>
<p style="top:401.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">The search identified 99 potentially relevant studies. Twenty-</span></p>
<p style="top:413.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">seven references met inclusion criteria (</span><b><span style="font-family:Minion,serif;font-size:10.0pt">Fig. 1</span></b><span style="font-family:Minion,serif;font-size:10.0pt">), including 19 </span></p>
<p style="top:425.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">preclinical references reporting 18 studies and eight clinical </span></p>
<p style="top:437.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">references reporting five clinical studies. One prospective </span></p>
<p style="top:449.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">clinical trial has been planned, but results are not available </span></p>
<p style="top:461.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(28). The presence of both clinical diversity and method-</span></p>
<p style="top:473.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ological diversity precluded combining the study reports in a </span></p>
<p style="top:485.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">meta-analysis.</span></p>
<p style="top:518.8pt;left:414.6pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">99 poten&#xfffd;ally </span></p>
<p style="top:526.3pt;left:407.6pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">relevant references</span></p>
<p style="top:541.4pt;left:464.3pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">71 references </span></p>
<p style="top:549.0pt;left:470.2pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">excluded</span></p>
<p style="top:565.2pt;left:408.0pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">27 studies mee&#xfffd;ng </span></p>
<p style="top:572.8pt;left:411.1pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">inclusion criteria</span></p>
<p style="top:599.9pt;left:463.1pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">8 human study </span></p>
<p style="top:607.5pt;left:468.6pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">references</span></p>
<p style="top:599.9pt;left:362.7pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">19 animal study </span></p>
<p style="top:607.5pt;left:369.4pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">references</span></p>
<p style="top:636.6pt;left:330.1pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">13 abstract </span></p>
<p style="top:644.2pt;left:338.9pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">only</span></p>
<p style="top:636.6pt;left:396.5pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">6 full </span></p>
<p style="top:644.2pt;left:387.3pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">manuscripts</span></p>
<p style="top:636.6pt;left:448.9pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">5 abstract </span></p>
<p style="top:644.2pt;left:456.1pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">only</span></p>
<p style="top:636.6pt;left:513.8pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">3 full </span></p>
<p style="top:644.2pt;left:504.5pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">manuscripts</span></p>
<p style="top:688.5pt;left:332.0pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">12 Studies</span></p>
<p style="top:662.3pt;left:312.4pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">1 Duplicate </span></p>
<p style="top:669.9pt;left:312.5pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">Publica&#xfffd;on</span></p>
<p style="top:662.3pt;left:370.4pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">0 Duplicate </span></p>
<p style="top:669.9pt;left:369.2pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">Publica&#xfffd;ons</span></p>
<p style="top:662.3pt;left:428.4pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">3 Duplicate </span></p>
<p style="top:669.9pt;left:427.3pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">Publica&#xfffd;ons</span></p>
<p style="top:662.3pt;left:486.5pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">0 Duplicate </span></p>
<p style="top:669.9pt;left:485.3pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">Publica&#xfffd;ons</span></p>
<p style="top:688.5pt;left:391.6pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">6 Studies</span></p>
<p style="top:688.5pt;left:449.7pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">2 Studies</span></p>
<p style="top:688.5pt;left:507.7pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">3 Studies</span></p>
<p style="top:540.9pt;left:363.7pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">1 human study </span></p>
<p style="top:548.4pt;left:368.7pt;line-height:6.3pt"><span style="font-family:Calibri,serif;font-size:6.3pt">in progress</span></p>
<p style="top:708.6pt;left:300.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Figure 1.</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> Schematic summary of literature review of nebulized anticoagu-</span></p>
<p style="top:717.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">lation regimens for the treatment of smoke inhalation&#x2013;associated acute </span></p>
<p style="top:726.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">lung injury.</span></p>


<p style="top:34.9pt;left:489.1pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Review Articles</span></p>
<p style="top:749.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">Critical Care Medicine </span></p>
<p style="top:751.4pt;left:423.4pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt"> </span></p>
<p style="top:749.8pt;left:532.8pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">415</span></b></p>
<p style="top:59.5pt;left:37.0pt;line-height:10.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">Preclinical Studies</span></b></p>
<p style="top:71.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">The bulk of the preclinical studies were conducted using an ovine </span></p>
<p style="top:83.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">model of SI-ALI. In this model, the sheep are surgically prepared </span></p>
<p style="top:95.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">for chronic study via placement of arterial, left atrial, pulmonary </span></p>
<p style="top:108.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">artery, and lung lymphatic catheters. On postoperative days 5&#x2013;7, </span></p>
<p style="top:120.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">smoke inhalation exposure is accomplished via either cooled cot-</span></p>
<p style="top:132.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ton (&lt; 40&#xb0;C) (13, 29&#x2013;45) or pinewood (46) smoke administered </span></p>
<p style="top:144.4pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">via tracheostomy or endotracheal tube. In most models, the ani-</span></p>
<p style="top:156.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">mals undergo cutaneous thermal burn (40% BSA) at the time </span></p>
<p style="top:168.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of smoke exposure. The animals are mechanically ventilated and </span></p>
<p style="top:180.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">volume resuscitated with IV crystalloid infusion in accordance </span></p>
<p style="top:192.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">with the Parkland formula (47). Antibiotic therapy is not admin-</span></p>
<p style="top:205.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">istered. The most commonly investigated nebulized anticoagula-</span></p>
<p style="top:217.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">tion regimens include unfractionated heparin (5,000 or 10,000 </span></p>
<p style="top:229.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">IU), AT (290 U), and TPA (1 or 2 mg) either alone or in combina-</span></p>
<p style="top:241.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">tion with anticoagulants. Depending on the study and treatment </span></p>
<p style="top:253.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">regimen, nebulized therapies are initiated at 1&#x2013;4 hours postin-</span></p>
<p style="top:265.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">jury and continued every 4 hours for, commonly, 24&#x2013;48 hours. </span></p>
<p style="top:277.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Endpoints are reported from 48 to 96 hours postinjury and </span></p>
<p style="top:290.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">usually include mortality, weaning from mechanical ventilation, </span></p>
<p style="top:59.5pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">and tracheostomy decannulation. Commonly reported markers </span></p>
<p style="top:71.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of ventilation and oxygenation include peak and plateau airway </span></p>
<p style="top:83.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">pressures, Pa</span><span style="font-family:Minion,serif;font-size:5.5pt">O</span><span style="font-family:Minion,serif;font-size:5.8pt">2</span><span style="font-family:Minion,serif;font-size:10.0pt">/F</span><span style="font-family:Minion,serif;font-size:5.5pt">IO</span><span style="font-family:Minion,serif;font-size:5.8pt">2</span><span style="font-family:Minion,serif;font-size:10.0pt">, and arterial-alveolar oxygen gradient. Mark-</span></p>
<p style="top:96.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ers of pulmonary congestion and obstruction include the lung </span></p>
<p style="top:108.1pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">wet-to-dry ratio (W/D), lung lymph flow, pulmonary shunt </span></p>
<p style="top:120.2pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">fraction (Qs/Qt), and histological obstruction scores. Other </span></p>
<p style="top:132.3pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">endpoints include the results of blood coagulation and clotting </span></p>
<p style="top:144.5pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">cascade variables and fluid balance. </span><b><span style="font-family:Minion,serif;font-size:10.0pt">Appendix 2</span></b><span style="font-family:Minion,serif;font-size:10.0pt"> (Supplemental </span></p>
<p style="top:156.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Digital Content 1, http://links.lww.com/CCM/A741) summa-</span></p>
<p style="top:168.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">rizes the results of 18 preclinical studies assessing inhaled antico-</span></p>
<p style="top:180.9pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">agulation regimens as treatment for SI-ALI.</span></p>
<p style="top:193.0pt;left:312.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Characteristic findings of SI-ALI as described by findings </span></p>
<p style="top:205.1pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">from control groups include the following: increased mortal-</span></p>
<p style="top:217.3pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ity and impaired ventilation with elevations in peak and pla-</span></p>
<p style="top:229.4pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">teau airway pressures, decline in Pa</span><span style="font-family:Minion,serif;font-size:5.5pt">O</span><span style="font-family:Minion,serif;font-size:5.8pt">2</span><span style="font-family:Minion,serif;font-size:10.0pt">/F</span><span style="font-family:Minion,serif;font-size:5.5pt">IO</span><span style="font-family:Minion,serif;font-size:5.8pt">2</span><span style="font-family:Minion,serif;font-size:10.0pt"> with concomitant </span></p>
<p style="top:241.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">rise in arterial-alveolar gradient, and increased evidence of </span></p>
<p style="top:253.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">airway obstruction. Increasing pulmonary congestion is often </span></p>
<p style="top:265.8pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">manifested as an increase in lung lymph flow, Qs/Qt, and W/D. </span></p>
<p style="top:278.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">With few exceptions, nebulized anticoagulation regimens sig-</span></p>
<p style="top:290.1pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">nificantly attenuated these findings (</span><b><span style="font-family:Minion,serif;font-size:10.0pt">Table 1).</span></b></p>
<p style="top:319.7pt;left:37.0pt;line-height:10.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">TabLE 1.</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:12.0pt"> Summary of the Pathophysiological Effects of Nebulized anticoagulation </span></b></p>
<p style="top:332.1pt;left:37.0pt;line-height:12.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:12.0pt">Regimens in animal Models of Smoke Inhalation&#x2013;associated acute Lung Injury</span></b></p>
<p style="top:380.3pt;left:46.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Reference</span></b></p>
<p style="top:353.3pt;left:174.8pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Inhaled </span></b></p>
<p style="top:362.3pt;left:175.4pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">antico-</span></b></p>
<p style="top:371.3pt;left:170.9pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">agulation </span></b></p>
<p style="top:380.3pt;left:172.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Regimen</span></b></p>
<p style="top:371.3pt;left:212.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Pa</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.5pt;color:#ffffff">O</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.7pt;color:#ffffff">2</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">/F</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.5pt;color:#ffffff">IO</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.7pt;color:#ffffff">2</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff"> </span></b></p>
<p style="top:380.3pt;left:219.2pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Ratio</span></b></p>
<p style="top:362.3pt;left:250.6pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">alveolar </span></b></p>
<p style="top:371.3pt;left:247.2pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">to arterial </span></b></p>
<p style="top:380.3pt;left:249.8pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Gradient</span></b></p>
<p style="top:362.3pt;left:300.3pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Shunt  </span></b></p>
<p style="top:371.3pt;left:295.9pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Fraction  </span></b></p>
<p style="top:380.3pt;left:299.9pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Qs/Qt</span></b></p>
<p style="top:371.3pt;left:338.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Wet-to-Dry </span></b></p>
<p style="top:380.3pt;left:348.4pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Ratio</span></b></p>
<p style="top:371.3pt;left:388.2pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Lymph  </span></b></p>
<p style="top:380.3pt;left:391.3pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Flow</span></b></p>
<p style="top:371.3pt;left:427.4pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">airway </span></b></p>
<p style="top:380.3pt;left:421.3pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Pressures</span></b></p>
<p style="top:371.3pt;left:465.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Histological </span></b></p>
<p style="top:380.3pt;left:465.3pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Obstruction Survival</span></b></p>
<p style="top:399.2pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Characteristic findings in  </span></p>
<p style="top:409.2pt;left:55.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">smoke inhalation&#x2013;associate </span></p>
<p style="top:419.2pt;left:55.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">acute lung injury</span></p>
<p style="top:399.5pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:399.5pt;left:264.4pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:399.5pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:399.5pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:399.5pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:399.5pt;left:438.3pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:399.5pt;left:484.9pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:399.5pt;left:528.6pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:435.4pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Desai et al (29)</span></p>
<p style="top:435.4pt;left:181.9pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1, 5</span></p>
<p style="top:435.7pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:435.7pt;left:528.6pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:451.9pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Brown et al (30)</span><sup><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.2pt">a</span></sup></p>
<p style="top:451.9pt;left:181.9pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1, 5</span></p>
<p style="top:452.3pt;left:528.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:468.5pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Cindric et al (31)</span></p>
<p style="top:468.5pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">4</span></p>
<p style="top:468.8pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:485.0pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Katahira et al (32)</span></p>
<p style="top:485.0pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1</span></p>
<p style="top:485.3pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:485.3pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:501.5pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Murakami et al (34)</span></p>
<p style="top:501.5pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1</span></p>
<p style="top:501.9pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:501.9pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:501.9pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:501.9pt;left:484.9pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:518.1pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Tasaki et al (46)</span></p>
<p style="top:518.1pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1</span></p>
<p style="top:518.4pt;left:264.4pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:518.1pt;left:291.1pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No change</span></p>
<p style="top:518.4pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:534.6pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Enkhbaatar et al (13)</span></p>
<p style="top:534.6pt;left:177.3pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1, 3, 6</span></p>
<p style="top:534.9pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:534.9pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:534.9pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:534.9pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:534.9pt;left:438.3pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:551.1pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Enkhbaatar et al (36)</span></p>
<p style="top:551.1pt;left:181.9pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">2, 6</span></p>
<p style="top:551.5pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:551.5pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:551.5pt;left:484.9pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:567.7pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Nakano et al (37)</span></p>
<p style="top:567.7pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">7</span></p>
<p style="top:568.0pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:568.0pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:584.2pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Enkhbaatar et al (38)</span></p>
<p style="top:584.2pt;left:177.3pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1, 3, 6</span></p>
<p style="top:584.5pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:584.5pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:584.5pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:584.5pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:584.5pt;left:438.3pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:600.7pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Enkhbaatar et al (39)</span></p>
<p style="top:600.7pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">7</span></p>
<p style="top:601.1pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:601.1pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:601.1pt;left:356.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:601.1pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:601.1pt;left:438.3pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:601.1pt;left:484.9pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:617.3pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Rehberg et al (40)</span></p>
<p style="top:617.3pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">8</span></p>
<p style="top:617.6pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:617.6pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:617.6pt;left:438.3pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:633.8pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Asmussen et al (41)</span></p>
<p style="top:633.8pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">8</span></p>
<p style="top:634.1pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:634.1pt;left:528.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:650.3pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Rehberg et al (42)</span></p>
<p style="top:650.3pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">8</span></p>
<p style="top:650.7pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:650.7pt;left:309.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:650.7pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:666.9pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Asmussen et al (45)</span></p>
<p style="top:666.9pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">8</span></p>
<p style="top:667.2pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:667.2pt;left:528.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:683.4pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Rehberg et al (44)</span></p>
<p style="top:683.4pt;left:186.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">8</span></p>
<p style="top:683.7pt;left:227.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2191;</span></p>
<p style="top:683.7pt;left:397.7pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:683.7pt;left:438.3pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:699.0pt;left:37.0pt;line-height:4.4pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.4pt">a</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">Due to high mortality in control and DMSO-alone groups, further comparisons were only made between heparin and DMSO + heparin groups.</span></p>
<p style="top:709.0pt;left:37.0pt;line-height:7.5pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">For studies presented, arrows indicate change from control or untreated groups, not overall change from baseline.</span></p>
<p style="top:719.0pt;left:37.0pt;line-height:7.5pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">Inhaled anticoagulation regimens: 1, heparin inhaled; 2, tissue plasminogen activator (tPA) inhaled; 3, antithrombin (AT) inhaled; 4, GM 1892 inhaled; 5, heparin </span></p>
<p style="top:727.0pt;left:37.0pt;line-height:7.5pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">inhaled + dimethyl sulfoxide inhaled; 6, heparin inhaled + AT inhaled; 7, heparin inhaled + AT IV; 8, heparin inhaled + tPA inhaled + AT IV.</span></p>


<p style="top:34.8pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Miller et al</span></p>
<p style="top:749.0pt;left:37.0pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">416</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:750.7pt;left:85.0pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:749.8pt;left:413.3pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">February&#xfffd;2014&#xfffd;&#x2022;&#xfffd;Volume&#xfffd;42&#xfffd;&#x2022;&#xfffd;Number&#xfffd;2</span></p>
<p style="top:615.9pt;left:37.0pt;line-height:10.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">Clinical Studies</span></b></p>
<p style="top:627.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Eight references accounting for five human clinical studies were </span></p>
<p style="top:639.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">identified (</span><b><span style="font-family:Minion,serif;font-size:10.0pt">Table 2</span></b><span style="font-family:Minion,serif;font-size:10.0pt">). Additionally, a prospective human study </span></p>
<p style="top:651.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">is planned but not yet recruiting patients (ClinicalTrials.gov </span></p>
<p style="top:663.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">#NCT014548690) (28). All human studies conducted to date </span></p>
<p style="top:675.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">have been retrospective studies with historical controls. Four </span></p>
<p style="top:687.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of the five studies were conducted around a change in institu-</span></p>
<p style="top:699.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">tional protocol (2, 27, 48, 49). Three studies assessed a low-dose </span></p>
<p style="top:711.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">heparin protocol (5,000 IU) (2, 49, 50) of which one treated </span></p>
<p style="top:723.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">according to physician discretion (50), and two studies assessed </span></p>
<p style="top:616.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">a high-dose heparin regimen (10,000 IU) (27, 48). The impact of </span></p>
<p style="top:628.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">the nebulized heparin protocols on common primary endpoints </span></p>
<p style="top:640.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">is summarized in </span><b><span style="font-family:Minion,serif;font-size:10.0pt">Table 3</span></b><span style="font-family:Minion,serif;font-size:10.0pt">. Both studies assessing a standardized </span></p>
<p style="top:652.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">high-dose heparin dosing regimen (10,000 IU nebulized every </span></p>
<p style="top:664.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">4 hr) reported statistically significant mortality improvement </span></p>
<p style="top:676.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(27, 48). Conversely, the one study that did not report a mortal-</span></p>
<p style="top:688.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ity benefit used a low-dose regimen, and unlike the aforemen-</span></p>
<p style="top:700.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">tioned studies, suffered from significant selection bias in that </span></p>
<p style="top:712.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">patients were not allocated into treatment groups but instead </span></p>
<p style="top:724.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">were treated according to physician discretion (50). Each of </span></p>
<p style="top:61.0pt;left:37.0pt;line-height:10.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">TabLE 2.</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:12.0pt"> Summary of Human Clinical Investigations of Inhaled anticoagulation for Smoke </span></b></p>
<p style="top:73.4pt;left:37.0pt;line-height:12.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:12.0pt">Inhalation&#x2013;associated acute Lung Injury</span></b></p>
<p style="top:94.6pt;left:46.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Reference</span></b></p>
<p style="top:94.6pt;left:119.1pt;line-height:8.0pt"><b><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">n</span></i></b></p>
<p style="top:94.6pt;left:170.7pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Protocol</span></b></p>
<p style="top:94.6pt;left:291.8pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Intervention</span></b></p>
<p style="top:94.6pt;left:458.7pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Results</span></b></p>
<p style="top:113.5pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Desai et al </span></p>
<p style="top:123.5pt;left:55.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">(2) </span></p>
<p style="top:113.5pt;left:116.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">90</span></p>
<p style="top:113.5pt;left:151.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Retrospective </span></p>
<p style="top:123.5pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">analysis with </span></p>
<p style="top:133.5pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">historical control</span></p>
<p style="top:113.5pt;left:241.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Standard therapy + heparin 5,000 U </span></p>
<p style="top:123.5pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">inhaled alternating with 3 mL NAC </span></p>
<p style="top:133.5pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">inhaled every 2 hr for first 7 d </span></p>
<p style="top:143.5pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">following injury</span></p>
<p style="top:113.8pt;left:407.0pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> Mortality, </span><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> reintubation rate, </span></p>
<p style="top:123.8pt;left:416.0pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> prevalence pneumonia and </span></p>
<p style="top:133.8pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">atelectasis; no significant </span></p>
<p style="top:143.8pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">change in duration of intubation</span></p>
<p style="top:160.0pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Rivero et al </span></p>
<p style="top:170.0pt;left:55.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">(48)</span><sup><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.2pt">a</span></sup></p>
<p style="top:160.0pt;left:116.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">16</span></p>
<p style="top:160.0pt;left:151.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Retrospective </span></p>
<p style="top:170.0pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">analysis with </span></p>
<p style="top:180.0pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">historical control</span></p>
<p style="top:160.0pt;left:241.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">The nebulized heparin 10,000 </span></p>
<p style="top:170.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">IU + NAC 3 mL of 20% group </span></p>
<p style="top:180.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">consisted of nine patients with </span></p>
<p style="top:190.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">smoke inhalation acute lung injury </span></p>
<p style="top:200.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">diagnosed with bronchoscopy and </span></p>
<p style="top:210.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">necessitating mechanical ventilation </span></p>
<p style="top:220.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">and Acute Physiology and Chronic </span></p>
<p style="top:230.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Health Evaluation III score &gt; 35 </span></p>
<p style="top:240.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">(mean 46.66 vs 44.86 [control], </span></p>
<p style="top:250.0pt;left:250.0pt;line-height:9.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">p</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> = 0.38); additionally, daily Lung </span></p>
<p style="top:260.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Injury Score was calculated for 7 d </span></p>
<p style="top:270.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">and was determined by averaging the </span></p>
<p style="top:280.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">scores of chest radiograph, Pa</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.5pt">o</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.2pt">2</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">/F</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.5pt">Io</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.2pt">2</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">, </span></p>
<p style="top:290.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">positive end-expiratory pressure, and </span></p>
<p style="top:300.0pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">respiratory system compliance</span></p>
<p style="top:160.0pt;left:407.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">In the first two ICU days, mean </span></p>
<p style="top:170.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">lung injury scores were </span></p>
<p style="top:180.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">significantly lower in the </span></p>
<p style="top:190.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">treatment group (0.76 &#xb1; 0.53 vs </span></p>
<p style="top:200.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1.23 &#xb1; 0.88; </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">p</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> = 0.08); mean </span></p>
<p style="top:210.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">lung injury score during the </span></p>
<p style="top:220.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">first week was 0.91 &#xb1; 0.14 vs </span></p>
<p style="top:230.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1.79 &#xb1; 0.41 (</span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">p</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> &lt; 0.01) for NH-</span></p>
<p style="top:240.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">NA and non-nebulized heparin </span></p>
<p style="top:250.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">and NAC patients, respectively; </span></p>
<p style="top:260.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">mortality was 11% (1/9) in the </span></p>
<p style="top:270.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">treatment group and 43% of </span></p>
<p style="top:280.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">patients (3/7) in the control </span></p>
<p style="top:290.0pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">group during the first ICU week</span></p>
<p style="top:316.2pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Holt et al </span></p>
<p style="top:326.2pt;left:55.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">(50)</span></p>
<p style="top:316.2pt;left:116.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">150</span></p>
<p style="top:316.2pt;left:151.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Retrospective </span></p>
<p style="top:326.2pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">analysis with </span></p>
<p style="top:336.2pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">historical control</span></p>
<p style="top:316.2pt;left:241.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No patient allocation; patients treated </span></p>
<p style="top:326.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">according to attending discretion; </span></p>
<p style="top:336.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">treated patients received inhaled </span></p>
<p style="top:346.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">heparin 5,000 U/1 mL, NAC 3 mL </span></p>
<p style="top:356.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">20% solution, and albuterol 2.5 mg </span></p>
<p style="top:366.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">of 0.083% solution (3 mL) every 4 hr </span></p>
<p style="top:376.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">for the first 7 d following admission </span></p>
<p style="top:386.2pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">or until extubation</span></p>
<p style="top:316.2pt;left:407.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No significant difference in </span></p>
<p style="top:326.2pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">mortality, duration of mechanical </span></p>
<p style="top:336.2pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">ventilation, length-of-stay, or </span></p>
<p style="top:346.2pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">pneumonia</span></p>
<p style="top:402.4pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Miller et al </span></p>
<p style="top:412.4pt;left:55.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">(27) </span></p>
<p style="top:402.4pt;left:116.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">30</span></p>
<p style="top:402.4pt;left:151.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Retrospective </span></p>
<p style="top:412.4pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">analysis with </span></p>
<p style="top:422.4pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">historical control</span></p>
<p style="top:402.4pt;left:241.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Standard therapy + heparin 10,000 U </span></p>
<p style="top:412.4pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">inhaled every 4 hr alternating with </span></p>
<p style="top:422.4pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">NAC 3 mL of 20% + albuterol </span></p>
<p style="top:432.4pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">0.5 mL every 4 hr</span></p>
<p style="top:402.7pt;left:407.0pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> Mortality, </span><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> lung injury score</span></p>
<p style="top:448.6pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Yip et al (49) </span></p>
<p style="top:448.6pt;left:116.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">63</span></p>
<p style="top:448.6pt;left:151.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Retrospective </span></p>
<p style="top:458.6pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">analysis with </span></p>
<p style="top:468.6pt;left:160.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">historical control</span></p>
<p style="top:448.6pt;left:241.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">1. Treatment group: mechanically </span></p>
<p style="top:458.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">ventilated adult patients with </span></p>
<p style="top:468.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">bronchoscopically confirmed SI-ALI </span></p>
<p style="top:478.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">admitted in a burn ICU (2006&#x2013;</span></p>
<p style="top:488.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">2009); treated with heparin 5,000 </span></p>
<p style="top:498.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">IU inhaled + NAC 600 mg/3 mL of </span></p>
<p style="top:508.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">20% aerosolized solution inhaled + </span></p>
<p style="top:518.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">salbutamol 5 mg inhaled, each every </span></p>
<p style="top:528.6pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">4 hr (</span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">n</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt"> = 52)</span></p>
<p style="top:448.6pt;left:407.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No significant difference in </span></p>
<p style="top:458.6pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">trend of activated partial </span></p>
<p style="top:468.6pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">thromboplastin time, prothrombin </span></p>
<p style="top:478.6pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">time, and platelet count over 7 d; </span></p>
<p style="top:488.6pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">no clinically significant increase </span></p>
<p style="top:498.6pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">in bleeding risk in treatment </span></p>
<p style="top:508.6pt;left:416.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">group</span></p>
<p style="top:544.8pt;left:241.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">2. Control: mechanically ventilated </span></p>
<p style="top:554.8pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">SI-ALI patients (2001&#x2013;2005) before </span></p>
<p style="top:564.8pt;left:250.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">protocol initiation</span></p>
<p style="top:580.4pt;left:37.0pt;line-height:7.5pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">NAC = </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">N</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">-acetylcysteine, SI-ALI = smoke inhalation&#x2013;associate acute lung injury.</span></p>
<p style="top:590.5pt;left:37.0pt;line-height:4.4pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.4pt">a</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">Published as abstract.</span></p>


<p style="top:34.9pt;left:489.1pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Review Articles</span></p>
<p style="top:749.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">Critical Care Medicine </span></p>
<p style="top:751.4pt;left:423.4pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt"> </span></p>
<p style="top:749.8pt;left:533.2pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">417</span></b></p>
<p style="top:241.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">three studies assessing lung injury score reported a statistically </span></p>
<p style="top:253.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">significant improvement (2, 27, 48). Only one standardized </span></p>
<p style="top:265.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">regimen (low dose) has assessed the prevalence of pneumonia, </span></p>
<p style="top:278.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">and this study reported a significant decrease in the prevalence </span></p>
<p style="top:241.2pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of pneumonia (2). These results were not reproduced by the </span></p>
<p style="top:253.5pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">study without a standardized dosing regimen (50). Although </span></p>
<p style="top:265.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">no change in the duration of mechanical ventilation has been </span></p>
<p style="top:278.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">reported with nebulized heparin regimens, one study did report </span></p>
<p style="top:290.3pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">a decrease in the prevalence </span></p>
<p style="top:302.6pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of </span></p>
<p style="top:302.6pt;left:444.9pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">unplanned </span></p>
<p style="top:302.6pt;left:498.9pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">reintubation </span></p>
<p style="top:314.9pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(2). Similar to animal studies, </span></p>
<p style="top:327.2pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">nebulized heparin regimens of </span></p>
<p style="top:339.5pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">5,000 IU or 10,000 IU every 4 </span></p>
<p style="top:351.8pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">hours in humans have not been </span></p>
<p style="top:364.1pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">shown to alter serum markers </span></p>
<p style="top:376.4pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of anticoagulation (49).</span></p>
<p style="top:404.8pt;left:425.4pt;line-height:11.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:11.0pt">DISCUSSION</span></b></p>
<p style="top:417.9pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Much of what is known of the </span></p>
<p style="top:430.2pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">early effects of smoke exposure </span></p>
<p style="top:442.5pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">on the respiratory tract has </span></p>
<p style="top:454.7pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">been described and validated </span></p>
<p style="top:467.0pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">in numerous ovine and lapine </span></p>
<p style="top:479.3pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">models of smoke inhalation </span></p>
<p style="top:491.6pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(51&#x2013;54). Although difficult </span></p>
<p style="top:503.9pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to study in humans, the time </span></p>
<p style="top:516.2pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">course of these physiological </span></p>
<p style="top:528.5pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">effects is comparable to those </span></p>
<p style="top:540.8pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">found in burned patients with </span></p>
<p style="top:553.1pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">smoke inhalation injury (51).</span></p>
<p style="top:565.4pt;left:437.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Thermal inhalation injury </span></p>
<p style="top:577.6pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">only rarely affects the intra-</span></p>
<p style="top:589.9pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">thoracic airways (55). Unless </span></p>
<p style="top:602.2pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">the patient is exposed to steam, </span></p>
<p style="top:614.5pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">which has much greater heat </span></p>
<p style="top:626.8pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">carrying capacity than dry air, </span></p>
<p style="top:639.1pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">the heat dissipating properties </span></p>
<p style="top:651.4pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">of the upper airway restrict </span></p>
<p style="top:663.7pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">direct thermal injury to the </span></p>
<p style="top:676.0pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">supraglottic structures (56, </span></p>
<p style="top:688.3pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">57). Intrathoracic and lower </span></p>
<p style="top:700.5pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">airway injury is most often </span></p>
<p style="top:712.8pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">a chemical-associated injury </span></p>
<p style="top:725.1pt;left:425.4pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">related to substances that have </span></p>
<p style="top:61.0pt;left:37.0pt;line-height:10.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">TabLE 3.</span></b><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:12.0pt"> Summary of the Pathophysiological and Clinical Effects of Nebulized Heparin </span></b></p>
<p style="top:73.4pt;left:37.0pt;line-height:12.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:12.0pt">Regimens in Human Clinical Studies of Smoke Inhalation&#x2013;associated acute Lung Injury</span></b></p>
<p style="top:112.6pt;left:46.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Reference</span></b></p>
<p style="top:103.6pt;left:121.5pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Lung Injury </span></b></p>
<p style="top:112.6pt;left:131.7pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Score</span></b></p>
<p style="top:103.6pt;left:176.2pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Pneumonia </span></b></p>
<p style="top:112.6pt;left:177.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Prevalence</span></b></p>
<p style="top:94.6pt;left:241.6pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Mechanical </span></b></p>
<p style="top:103.6pt;left:242.5pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Ventilation </span></b></p>
<p style="top:112.6pt;left:246.7pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Duration</span></b></p>
<p style="top:103.6pt;left:310.9pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Unplanned </span></b></p>
<p style="top:112.6pt;left:306.8pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Reintubation</span></b></p>
<p style="top:103.6pt;left:368.8pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Hospital Length </span></b></p>
<p style="top:112.6pt;left:385.6pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">of Stay</span></b></p>
<p style="top:112.6pt;left:441.6pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">bleeding Risk</span></b></p>
<p style="top:112.6pt;left:510.3pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt;color:#ffffff">Mortality</span></b></p>
<p style="top:131.5pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Desai et al (2) </span></p>
<p style="top:131.8pt;left:140.8pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:131.8pt;left:196.0pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:131.5pt;left:242.8pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No change</span></p>
<p style="top:131.8pt;left:329.8pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:148.0pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Rivero et al (48) </span></p>
<p style="top:148.4pt;left:140.8pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:148.4pt;left:525.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:164.6pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Holt et al (50)</span><sup><span style="font-family:AkzidenzGroteskBE,serif;font-size:5.2pt">a</span></sup></p>
<p style="top:164.6pt;left:177.5pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No change</span></p>
<p style="top:164.6pt;left:378.6pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No change</span></p>
<p style="top:164.6pt;left:506.9pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No change</span></p>
<p style="top:180.8pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Miller et al (27)</span></p>
<p style="top:181.1pt;left:140.8pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:181.1pt;left:525.5pt;line-height:9.0pt"><span style="font-family:GandhariUnicode,serif;font-size:9.0pt">&#x2193;</span></p>
<p style="top:197.3pt;left:46.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Yip et al (49)</span></p>
<p style="top:197.3pt;left:447.7pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">No change</span></p>
<p style="top:212.6pt;left:37.0pt;line-height:4.4pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:4.4pt">a</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">No randomization or allocation into treatment groups. Patients treated at attending physician discretion with a dosing regimen half the strength of the studies by </span></p>
<p style="top:220.6pt;left:37.0pt;line-height:7.5pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.5pt">Rivero et al (48) and Miller et al (27).</span></p>
<img style="position:absolute;transform:matrix(.47999997,0,-0,.4795518,-201.7666,221.13172)" src="data:image/jpeg;base64,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">
<p style="top:573.6pt;left:37.0pt;line-height:8.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Figure 2.</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> Depiction of airway changes in the setting of smoke inhalation&#x2013;associated acute lung injury. Trachea </span></p>
<p style="top:582.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and bronchi injury is characterized by mucosal hyperemia, increased microvascular permeability, exfoliation of </span></p>
<p style="top:591.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">the epithelial lining, mucous secretion, and an acute inflammatory cell influx (</span><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">a&#x2013;C</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">) (57). As early as 1 hr postex-</span></p>
<p style="top:600.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">posure, affected respiratory tract epithelium may display clumping, swelling, loss of cilia, blebbing, and surface </span></p>
<p style="top:609.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">erosion (B) (55). Within hours, sloughing of the respiratory mucosa progresses, a fibrinocellular pseudomem-</span></p>
<p style="top:618.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">brane begins to form, and neutrophils begin to influx into the major airways (55). By 6 hr postinjury, the injured </span></p>
<p style="top:627.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">bronchi and bronchiole epithelium remains largely intact with focal areas of necrosis and sloughing (A, B) (56). </span></p>
<p style="top:636.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Surface lining cells appear enlarged with cytoplasmic vacuolization, and neutrophils have begun to marginate </span></p>
<p style="top:645.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and focally concentrate at points of epithelial necrosis (56). In addition, basal cells are normal in appearance, </span></p>
<p style="top:654.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and the subepithelial connective tissue may appear slightly edematous with contained neutrophil infiltrates (56). </span></p>
<p style="top:663.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">By 24 hr, the ciliated and secretory lining cells are largely destroyed (C) (56). Cellular debris is admixed with </span></p>
<p style="top:672.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">fibroid material, mucus, and neutrophils creating a pseudomembranous fibrinocellular network that is adherent </span></p>
<p style="top:681.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">to both the cell-denuded basal lamina and the intact basal cells (C, </span><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">D</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">) (56). By 72 hr, injured epithelial areas </span></p>
<p style="top:690.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">are largely resurfaced by a stratified reparative epithelium with interposed areas of fibrinocellular exudate (D) </span></p>
<p style="top:699.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">(56). This epithelium is three to five cells thick, with flattened, nonciliated cells along the surface, and these cells </span></p>
<p style="top:708.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">are likely derived from proliferating and migrating basal cells (56). Subepithelial edema and inflammatory cell </span></p>
<p style="top:717.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">infiltrates begin to diminish (56). Complete repair of the respiratory tract epithelium with return of normal cilia </span></p>
<p style="top:726.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">populations may take up to 2&#x2013;4 wk depending on the severity of smoke exposure.</span></p>


<p style="top:34.8pt;left:37.0pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Miller et al</span></p>
<p style="top:749.0pt;left:37.0pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">418</span></b><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:750.7pt;left:85.0pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">&#xfffd;</span></p>
<p style="top:749.8pt;left:413.3pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">February&#xfffd;2014&#xfffd;&#x2022;&#xfffd;Volume&#xfffd;42&#xfffd;&#x2022;&#xfffd;Number&#xfffd;2</span></p>
<p style="top:59.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">lower water solubility and particles less than 5 microns in </span></p>
<p style="top:71.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">diameter (58).</span></p>
<p style="top:83.8pt;left:49.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Inhaled toxicants can be in the form of gases, vapors, partic-</span></p>
<p style="top:95.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ulate matter, and aerosols (57). Smoke from combustible mate-</span></p>
<p style="top:108.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">rial contains a variety of toxic substances that may cause direct </span></p>
<p style="top:120.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">cell injury and initiate inflammatory responses that propagate </span></p>
<p style="top:132.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">airway damage (55, 57, 58). Additionally, inhaled particulate </span></p>
<p style="top:144.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">matter (i.e., soot) may have adsorbed toxic molecules on the </span></p>
<p style="top:156.4pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">surfaces and sustain inflammatory responses when adherent to </span></p>
<p style="top:168.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">the airway mucosa (57).</span></p>
<p style="top:180.6pt;left:49.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">The initial injury from smoke inhalation is limited to the tra-</span></p>
<p style="top:192.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">chea and bronchi and is characterized by mucosal hyperemia, </span></p>
<p style="top:204.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">increased microvascular permeability, exfoliation of the epithe-</span></p>
<p style="top:216.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">lial lining, mucous secretion, and an acute inflammatory cell </span></p>
<p style="top:229.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">influx (</span><b><span style="font-family:Minion,serif;font-size:10.0pt">Fig. 2 </span></b><b><i><span style="font-family:Minion,serif;font-size:10.0pt">A</span></i></b><b><span style="font-family:Minion,serif;font-size:10.0pt">&#x2013;</span></b><b><i><span style="font-family:Minion,serif;font-size:10.0pt">C</span></i></b><b><span style="font-family:Minion,serif;font-size:10.0pt">)</span></b><span style="font-family:Minion,serif;font-size:10.0pt"> (53). Necrosis and sloughing of tracheal epi-</span></p>
<p style="top:241.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">thelium has been reported as early as 15 minutes postexposure </span></p>
<p style="top:253.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(51). Bronchi obstruction peaks as early as 24 hours, whereas </span></p>
<p style="top:265.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">bronchiolar obstruction progressively increases to reach a max-</span></p>
<p style="top:277.4pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">imum by 72 hours (</span><b><span style="font-family:Minion,serif;font-size:10.0pt">Fig. 2</span></b><b><i><span style="font-family:Minion,serif;font-size:10.0pt">D</span></i></b><b><span style="font-family:Minion,serif;font-size:10.0pt">)</span></b><span style="font-family:Minion,serif;font-size:10.0pt"> (51, 53). This may be in part due to </span></p>
<p style="top:289.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">obstructive material that migrates distally from larger airways </span></p>
<p style="top:301.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to smaller bronchioles and disruption of mucociliary clearance </span></p>
<p style="top:313.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(53). As highlighted in Figure 2, fundamental to the airway </span></p>
<p style="top:325.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">obstruction is the role of increased microvascular permeabil-</span></p>
<p style="top:337.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ity and airway edema that results in plasma exudation into the </span></p>
<p style="top:350.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">airway producing intra-airway coagulation and fibrin deposits. </span></p>
<p style="top:362.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">These deposits lead to with the resultant fibrinocellular pseu-</span></p>
<p style="top:374.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">domembranes composed of fibrin deposition, cellular debris, </span></p>
<p style="top:386.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">and mucin. A dose-dependent relationship between degree of </span></p>
<p style="top:398.4pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">smoke exposure and severity of injury has been described (55).</span></p>
<p style="top:410.5pt;left:49.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">As intra-airway coagulation with fibrin deposition and fibrino-</span></p>
<p style="top:422.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">cellular pseudomembranes begin to form within hours of smoke </span></p>
<p style="top:434.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">exposure, inhaled anticoagulation regimens may be most effec-</span></p>
<p style="top:446.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">tive when initiated early under the premise that impairing fibrin </span></p>
<p style="top:458.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">clot deposition may decrease airway cast formation and improve </span></p>
<p style="top:471.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">oxygenation and ventilation while decreasing the risk of baro-</span></p>
<p style="top:483.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">trauma. Preclinical models (Appendix 2, Supplemental Digital </span></p>
<p style="top:495.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Content 1, http://links.lww.com/CCM/A741) most commonly </span></p>
<p style="top:507.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">initiated therapy at 1&#x2013;2 hours (range, 0.5&#x2013;4 hr) postinjury and </span></p>
<p style="top:519.4pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">continued every 4 hours for usually 48 hours (range, 24&#x2013;96 hr). </span></p>
<p style="top:531.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Human studies did not reliably report time from smoke exposure </span></p>
<p style="top:543.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to treatment initiation. Based on preclinical studies, it may be rea-</span></p>
<p style="top:555.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">sonable to initiate a regimen of inhaled heparin within 4 hours </span></p>
<p style="top:567.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">postexposure (or as early as possible) and to continue it every 4 </span></p>
<p style="top:579.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">hours for 48 hours. In animal models, 72 hours injured epithelial </span></p>
<p style="top:592.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">areas are largely resurfaced by a stratified reparative epithelium </span></p>
<p style="top:604.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">with only interposed areas of fibrinocellular exudate (Fig. 2</span><i><span style="font-family:Minion,serif;font-size:10.0pt">D</span></i><span style="font-family:Minion,serif;font-size:10.0pt">) </span></p>
<p style="top:616.2pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(52). Additional factors that contribute to airway cast formation </span></p>
<p style="top:628.3pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">are mucus secretion and the presence of a large burden of cellular </span></p>
<p style="top:640.4pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">debris. The addition of the mucolytic </span><i><span style="font-family:Minion,serif;font-size:10.0pt">N</span></i><span style="font-family:Minion,serif;font-size:10.0pt">-acetylcysteine to nebu-</span></p>
<p style="top:652.5pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">lized heparin regimens intervenes at an additional level to pre-</span></p>
<p style="top:664.6pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">vent or minimize formation of obstructive airway casts (2, 27, 48, </span></p>
<p style="top:676.7pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">59). Future studies in SI-ALI may use combination therapy with </span></p>
<p style="top:688.8pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">inhaled heparin, an inhaled fibrinolytic (e.g., TPA), and muco-</span></p>
<p style="top:700.9pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">lytic therapy (e.g., </span><i><span style="font-family:Minion,serif;font-size:10.0pt">N</span></i><span style="font-family:Minion,serif;font-size:10.0pt">-acetylcysteine). Furthermore, recombinant </span></p>
<p style="top:713.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">human deoxyribonuclease I (dornase alfa) cleaves extracellular </span></p>
<p style="top:725.1pt;left:37.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">DNA in mucous and when inhaled reduces the adhesiveness and </span></p>
<p style="top:59.6pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">viscoelasticity of airway mucous in patients with cystic fibrosis </span></p>
<p style="top:71.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">(60). This treatment might augment the breakdown of cellular </span></p>
<p style="top:83.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">debris and further impede the formation of fibrinocellular pseu-</span></p>
<p style="top:95.7pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">domembranes. However, to date, no studies using this strategy in </span></p>
<p style="top:107.8pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">the setting of SI-ALI have been reported.</span></p>
<p style="top:137.0pt;left:300.0pt;line-height:11.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:11.0pt">CONCLUSION</span></b></p>
<p style="top:149.8pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">The high mortality associated with SI-ALI results from airway </span></p>
<p style="top:161.9pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">epithelial cell injury and inflammation, mucosal dysfunction, </span></p>
<p style="top:173.9pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">airway coagulopathy with cast formation resulting in ventila-</span></p>
<p style="top:185.9pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">tion-perfusion mismatch with shunt, and barotrauma. Inhaled </span></p>
<p style="top:198.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">anticoagulation regimens in both preclinical and clinical stud-</span></p>
<p style="top:210.0pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">ies decrease morbidity without altering systemic markers of </span></p>
<p style="top:222.1pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">clotting and anticoagulation. In some preclinical and clinical </span></p>
<p style="top:234.1pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">studies, inhaled anticoagulants were associated with a favorable </span></p>
<p style="top:246.1pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">effect on survival. This approach appears sufficiently promising </span></p>
<p style="top:258.2pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">to merit a well-designed prospective study to validate its use in </span></p>
<p style="top:270.2pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">patients with severe SI-ALI requiring mechanical ventilation.</span></p>
<p style="top:299.5pt;left:300.0pt;line-height:11.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:11.0pt">aCKNOWLEDGMENTS</span></b></p>
<p style="top:312.3pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">We thank Judith Welsh for her assistance and expertise with the </span></p>
<p style="top:324.4pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">literature search and search strategies. Additionally, we thank </span></p>
<p style="top:336.4pt;left:300.0pt;line-height:10.0pt"><span style="font-family:Minion,serif;font-size:10.0pt">Kelly Byrne for her assistance in developing the artwork.</span></p>
<p style="top:365.6pt;left:300.0pt;line-height:11.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:11.0pt">REFERENCES</span></b></p>
<p style="top:377.1pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1. Association AB: Burn incidence and treatment in the United States: </span></p>
<p style="top:386.1pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2011 Fact Sheet. American Burn Association National Burn </span></p>
<p style="top:395.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Repository (2011 report) 2011. Available at: http://www.ameriburn.</span></p>
<p style="top:404.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">org/resources_factsheet.php. Accessed November 14, 2012</span></p>
<p style="top:415.2pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2. Desai MH, Mlcak R, Richardson J, et al: Reduction in mortality in pedi-</span></p>
<p style="top:424.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">atric patients with inhalation injury with aerosolized heparin/N-acet-</span></p>
<p style="top:433.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">ylcystine [correction of acetylcystine] therapy. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Burn Care Rehabil</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:442.4pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">1998; 19:210&#x2013;212</span></p>
<p style="top:453.4pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 3. Luo G, Peng Y, Yuan Z, et al: Inhalation injury in southwest China&#x2014;The </span></p>
<p style="top:462.4pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">evolution of care. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2010; 36:506&#x2013;510</span></p>
<p style="top:473.5pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 4. Thompson PB, Herndon DN, Traber DL, et al: Effect on mortality of </span></p>
<p style="top:482.5pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Trauma</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1986; 26:163&#x2013;165</span></p>
<p style="top:493.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 5. Dai NT, Chen TM, Cheng TY, et al: The comparison of early fluid ther-</span></p>
<p style="top:502.6pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">apy in extensive flame burns between inhalation and noninhalation </span></p>
<p style="top:511.6pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">injuries. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1998; 24:671&#x2013;675</span></p>
<p style="top:522.7pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 6. Suzuki M, Aikawa N, Kobayashi K, et al: Prognostic implications of </span></p>
<p style="top:531.7pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury in burn patients in Tokyo. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2005; 31:331&#x2013;336</span></p>
<p style="top:542.8pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 7. Tredget EE, Shankowsky HA, Taerum TV, et al: The role of inhala-</span></p>
<p style="top:551.8pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">tion injury in burn trauma. A Canadian experience. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Ann Surg</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1990; </span></p>
<p style="top:560.8pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">212:720&#x2013;727</span></p>
<p style="top:571.9pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 8. Shirani KZ, Pruitt BA Jr, Mason AD Jr: The influence of inhalation injury </span></p>
<p style="top:580.9pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and pneumonia on burn mortality. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Ann Surg</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1987; 205:82&#x2013;87</span></p>
<p style="top:592.0pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 9. Hollingsed TC, Saffle JR, Barton RG, et al: Etiology and conse-</span></p>
<p style="top:601.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">quences of respiratory failure in thermally injured patients. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Am J Surg</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:610.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">1993; 166:592&#x2013;596</span></p>
<p style="top:621.1pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 10. Mlcak RP: Aerosolized heparin/N acetylcystine treatment of smoke </span></p>
<p style="top:630.1pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury in 596 burned children: A 15 year review, 1990&#x2013;</span></p>
<p style="top:639.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2005. Saliba MJ (Ed). 6th International Heparin in Burns Symposium. </span></p>
<p style="top:648.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Shanghai, China, 2005</span></p>
<p style="top:659.2pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 11. Blinn DL, Slater H, Goldfarb IW: Inhalation injury with burns: A lethal </span></p>
<p style="top:668.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">combination. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Emerg Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1988; 6:471&#x2013;473</span></p>
<p style="top:679.3pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 12. Stothert JC Jr, Ashley KD, Kramer GC, et al: Intrapulmonary distribu-</span></p>
<p style="top:688.4pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">tion of bronchial blood flow after moderate smoke inhalation. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Appl </span></i></p>
<p style="top:697.4pt;left:315.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Physiol</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1990; 69:1734&#x2013;1739</span></p>
<p style="top:708.4pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 13. Enkhbaatar P, Murakami K, Westphal M, et al: Combined antithrombin </span></p>
<p style="top:717.5pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and heparin nebulization improves pulmonary function in sheep with </span></p>
<p style="top:726.5pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">burn and smoke inhalation: 96. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2004; 32:A24</span></p>


<p style="top:34.9pt;left:489.1pt;line-height:9.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">Review Articles</span></p>
<p style="top:749.0pt;left:37.0pt;line-height:10.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt">Critical Care Medicine </span></p>
<p style="top:751.4pt;left:423.4pt;line-height:7.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:7.0pt">www.ccmjournal.org</span><span style="font-family:AkzidenzGroteskBE,serif;font-size:10.0pt"> </span></p>
<p style="top:749.8pt;left:532.8pt;line-height:9.0pt"><b><span style="font-family:AkzidenzGroteskBE,serif;font-size:9.0pt">419</span></b></p>
<p style="top:59.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 14. Jacob S, Kraft R, Zhu Y, et al: Acute secretory cell toxicity and epi-</span></p>
<p style="top:68.6pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">thelial exfoliation after smoke inhalation injury in sheep: An elec-</span></p>
<p style="top:77.6pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">tron and light microscopic study. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Toxicol Mech Methods</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2010; </span></p>
<p style="top:86.6pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">20:504&#x2013;509</span></p>
<p style="top:97.6pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 15. Choi WI, Syrkina O, Kwon KY, et al: JNK activation is responsible for </span></p>
<p style="top:106.6pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">mucus overproduction in smoke inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Respir Res</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2010; </span></p>
<p style="top:115.6pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">11:172</span></p>
<p style="top:126.7pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 16. Cox RA, Burke AS, Traber DL, et al: Production of pro-inflammatory </span></p>
<p style="top:135.7pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">polypeptides by airway mucous glands and its potential significance. </span></p>
<p style="top:144.7pt;left:52.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Pulm Pharmacol Ther</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2007; 20:172&#x2013;177</span></p>
<p style="top:155.7pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 17. Morita N, Enkhbaatar P, Maybauer DM, et al: Impact of bronchial cir-</span></p>
<p style="top:164.7pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">culation on bronchial exudates following combined burn and smoke </span></p>
<p style="top:173.7pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury in sheep. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2011; 37:465&#x2013;473</span></p>
<p style="top:184.7pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 18. Hill IR: Reactions to particles in smoke. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Toxicology</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1996; 115: </span></p>
<p style="top:193.7pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">119&#x2013;122</span></p>
<p style="top:204.7pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 19. Murakami K, Traber DL: Pathophysiological basis of smoke inhalation </span></p>
<p style="top:213.7pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">News Physiol Sci</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2003; 18:125&#x2013;129</span></p>
<p style="top:224.7pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 20. Cox RA, Mlcak RP, Chinkes DL, et al: Upper airway mucus deposition </span></p>
<p style="top:233.7pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">in lung tissue of burn trauma victims. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Shock</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2008; 29:356&#x2013;361</span></p>
<p style="top:244.8pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 21. Fitzpatrick JC, Cioffi WG Jr, Cheu HW, et al: Predicting ventila-</span></p>
<p style="top:253.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">tion failure in children with inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Pediatr Surg</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1994; </span></p>
<p style="top:262.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">29:1122&#x2013;1126</span></p>
<p style="top:273.8pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 22. Saliba MJ Jr: Heparin in the treatment of burns: A review. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2001; </span></p>
<p style="top:282.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">27:349&#x2013;358</span></p>
<p style="top:293.8pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 23. Hamahata A, Enkhbaatar P, Sakurai H, et al: Effect of ablated bron-</span></p>
<p style="top:302.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">chial blood flow on survival rate and pulmonary function after burn and </span></p>
<p style="top:311.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">smoke inhalation in sheep. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2009; 35:802&#x2013;810</span></p>
<p style="top:322.8pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 24. Traber DL, Hawkins HK, Enkhbaatar P, et al: The role of the bronchial </span></p>
<p style="top:331.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">circulation in the acute lung injury resulting from burn and smoke inha-</span></p>
<p style="top:340.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">lation. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Pulm Pharmacol Ther</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2007; 20:163&#x2013;166</span></p>
<p style="top:351.8pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 25. Westphal M, Cox RA, Traber LD, et al: Combined burn and smoke </span></p>
<p style="top:360.8pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury impairs ovine hypoxic pulmonary vasoconstriction. </span></p>
<p style="top:369.9pt;left:52.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2006; 34:1428&#x2013;1436</span></p>
<p style="top:380.9pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 26. Cancio LC: Airway management and smoke inhalation injury in the </span></p>
<p style="top:389.9pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">burn patient. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Clin Plast Surg</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2009; 36:555&#x2013;567</span></p>
<p style="top:400.9pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 27. Miller AC, Rivero A, Ziad S, et al: Influence of nebulized unfraction-</span></p>
<p style="top:409.9pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">ated heparin and N-acetylcysteine in acute lung injury after smoke </span></p>
<p style="top:418.9pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Burn Care Res</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2009; 30:249&#x2013;256</span></p>
<p style="top:429.9pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 28. Salehi SH: The effect of heparin on inhalation injury. Available at: </span></p>
<p style="top:438.9pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">http://clinicaltrials.gov. Accessed October 10, 2012</span></p>
<p style="top:449.9pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">29. Desai MH, Brown M, Mlcak R, et al: Nebulization treatment of smoke-</span></p>
<p style="top:458.9pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury in sheep model with dimethylsulfoxide, heparin, com-</span></p>
<p style="top:467.9pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">bination and N-acetylcysteine. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1986; 14:321</span></p>
<p style="top:478.9pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 30. Brown M, Desai M, Traber LD, et al: Dimethylsulfoxide with heparin in </span></p>
<p style="top:488.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">the treatment of smoke inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Burn Care Rehabil</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1988; </span></p>
<p style="top:497.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">9:22&#x2013;25</span></p>
<p style="top:508.0pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 31. Cindrick L, Schenarts P, Bone H, et al: Nebulization of a non-antico-</span></p>
<p style="top:517.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">agulant heparinoid (gm1892) attenuates lung lymph flow after acute </span></p>
<p style="top:526.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">lung injury in sheep. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">FASEB J</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1996; 10:A353</span></p>
<p style="top:537.0pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 32. Katahira J, Murakami K, Mlcak R, et al: Effect of heparin nebulization </span></p>
<p style="top:546.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">in burn and smoke inhalation injury in sheep. ATS 2001&#x2014;American </span></p>
<p style="top:555.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Thoracic Society International Conference, San Francisco, CA, 2001</span></p>
<p style="top:566.0pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 33. Suman OE, Mlcak RP, Katahira J, et al: Effects of nebulized hepa-</span></p>
<p style="top:575.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">rin on pulmonary mechanics following smoke inhalation injury. ATS </span></p>
<p style="top:584.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2001&#x2014;American Thoracic Society International Conference, San </span></p>
<p style="top:593.0pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Francisco, CA, 2001</span></p>
<p style="top:604.0pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 34. Murakami K, Cox R, Hawkins H, et al: Recombinant antithrombin </span></p>
<p style="top:613.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">(RhAT) inhibits airway obstruction after smoke inhalation in sheep. </span></p>
<p style="top:622.1pt;left:52.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">FASEB J</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2002; 16:A76</span></p>
<p style="top:633.1pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 35. Thomas S, Suman OE, Enkhbaatar P, et al: The effect of tissue </span></p>
<p style="top:642.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">plasminogen activator on pulmonary diffusion capacity in a burn </span></p>
<p style="top:651.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">and smoke inhalation sheep model. ATS 2004&#x2014;American Thoracic </span></p>
<p style="top:660.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Society International Conference, Orlando, FL, 2004</span></p>
<p style="top:671.1pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 36. Enkhbaatar P, Cox R, Morita N, et al: Role of airway fibrin formation </span></p>
<p style="top:680.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">in pathogenesis of acute lung injury. ATS 2005&#x2014;American Thoracic </span></p>
<p style="top:689.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Society International Conference, San Diego, CA, 2005</span></p>
<p style="top:700.1pt;left:37.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 37. Nakano YY, Enkhbaatar P, Traber LD, et al: Effect of aerosolized hepa-</span></p>
<p style="top:709.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">rin with recombinant human antithrombin (rhAT) supplementation in </span></p>
<p style="top:718.1pt;left:52.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">ovine septic shock. ATS 2006&#x2014;American Thoracic Society, 2006</span></p>
<p style="top:59.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 38. Enkhbaatar P, Cox RA, Traber LD, et al: Aerosolized anticoagulants </span></p>
<p style="top:68.7pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">ameliorate acute lung injury in sheep after exposure to burn and </span></p>
<p style="top:77.7pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">smoke inhalation. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2007; 35:2805&#x2013;2810</span></p>
<p style="top:88.8pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 39. Enkhbaatar P, Esechie A, Wang J, et al: Combined anticoagulants </span></p>
<p style="top:97.8pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">ameliorate acute lung injury in sheep after burn and smoke inhalation. </span></p>
<p style="top:106.8pt;left:315.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Clin Sci (Lond)</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2008; 114:321&#x2013;329</span></p>
<p style="top:117.9pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 40. Rehberg S, Yamamoto Y, Traber D, et al: Intravenous antithrombin </span></p>
<p style="top:126.9pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">III combined with nebulized heparin and tissue plasminogen activa-</span></p>
<p style="top:136.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">tor improves pulmonary function following combined burn and smoke </span></p>
<p style="top:145.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2009; 37:A168</span></p>
<p style="top:156.0pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 41. Asmussen S, Yamamoto Y, Traber DL, et al: Combined anticoagu-</span></p>
<p style="top:165.1pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">lant and fibrinolytic therapy decreases the ventilator days in an ovine </span></p>
<p style="top:174.1pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">model of cutaneous burn and smoke inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:183.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2010; 38:A94</span></p>
<p style="top:194.2pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 42. Rehberg S, Bartha E, Yamamoto Y, et al: Cardiovascular dysfunction </span></p>
<p style="top:203.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">induced by combined burn and smoke inhalation injury is attenuated </span></p>
<p style="top:212.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">by maintaining physiological plasma levels of antithrombin. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Intensive </span></i></p>
<p style="top:221.3pt;left:315.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2010; 36:S320</span></p>
<p style="top:232.4pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 43. Rehberg S, Maybauer MO, Enkhbaatar P, et al: Pathophysiology, </span></p>
<p style="top:241.4pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">management and treatment of smoke inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Expert Rev </span></i></p>
<p style="top:250.4pt;left:315.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Respir Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2009; 3:283&#x2013;297</span></p>
<p style="top:261.5pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 44. Rehberg S, Sousse L, Yamamoto Y, et al: Interactions of nebulized </span></p>
<p style="top:270.5pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">heparin with intravenous antithrombin for combined therapy of acute </span></p>
<p style="top:279.6pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">lung injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2011; 15:S72&#x2013;S73</span></p>
<p style="top:290.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 45. Asmussen S, Yamamoto Y, Traber DL, et al: Therapy with recombi-</span></p>
<p style="top:299.6pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">nant human antithrombin, heparin and tissue plasminogen activator </span></p>
<p style="top:308.7pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">improves survival and reduces ventilation days in a long-term ovine </span></p>
<p style="top:317.7pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">model of cutaneous burn and smoke inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2011; </span></p>
<p style="top:326.8pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">15:S64</span></p>
<p style="top:337.8pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 46. Tasaki O, Mozingo DW, Dubick MA, et al: Effects of heparin and liso-</span></p>
<p style="top:346.8pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">fylline on pulmonary function after smoke inhalation injury in an ovine </span></p>
<p style="top:355.9pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">model. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2002; 30:637&#x2013;643</span></p>
<p style="top:366.9pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 47. Baxter CR: Fluid volume and electrolyte changes of the early post-</span></p>
<p style="top:376.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">burn period. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Clin Plast Surg</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1974; 1:693&#x2013;703</span></p>
<p style="top:387.0pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 48. Rivero A, Elamin E, Nguyen V, et al: Can nebulized heparin and </span></p>
<p style="top:396.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">N-acetylcysteine reduce acute lung injury after inhalation lung insult? </span></p>
<p style="top:405.1pt;left:315.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Chest</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2007; 132:565S</span></p>
<p style="top:416.1pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 49. Yip LY, Lim YF, Chan HN: Safety and potential anticoagulant effects of </span></p>
<p style="top:425.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">nebulised heparin in burns patients with inhalational injury at Singapore </span></p>
<p style="top:434.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">General Hospital Burns Centre. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Burns</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2011; 37:1154&#x2013;1160</span></p>
<p style="top:445.2pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 50. Holt J, Saffle JR, Morris SE, et al: Use of inhaled heparin/N-acetyl-</span></p>
<p style="top:454.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">cystine in inhalation injury: Does it help? </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Burn Care Res</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2008; </span></p>
<p style="top:463.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">29:192&#x2013;195</span></p>
<p style="top:474.4pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 51. Hubbard GB, Langlinais PC, Shimazu T, et al: The morphology of </span></p>
<p style="top:483.4pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">smoke inhalation injury in sheep. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Trauma</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1991; 31:1477&#x2013;1486</span></p>
<p style="top:494.4pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 52. Thorning DR, Howard ML, Hudson LD, et al: Pulmonary responses </span></p>
<p style="top:503.5pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">to smoke inhalation: Morphologic changes in rabbits exposed to pine </span></p>
<p style="top:512.5pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">wood smoke. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Hum Pathol</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1982; 13:355&#x2013;364</span></p>
<p style="top:523.6pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 53. Cox RA, Burke AS, Soejima K, et al: Airway obstruction in sheep with </span></p>
<p style="top:532.6pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">burn and smoke inhalation injuries. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Am J Respir Cell Mol Biol</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2003; </span></p>
<p style="top:541.6pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">29:295&#x2013;302</span></p>
<p style="top:552.7pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 54. Linares HA, Herndon DN, Traber DL: Sequence of morphologic </span></p>
<p style="top:561.7pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">events in experimental smoke inhalation. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">J Burn Care Rehabil</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1989; </span></p>
<p style="top:570.8pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">10:27&#x2013;37</span></p>
<p style="top:581.8pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 55. Lee AS, Mellins RB: Lung injury from smoke inhalation. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Paediatr </span></i></p>
<p style="top:590.8pt;left:315.0pt;line-height:8.0pt"><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Respir Rev</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 2006; 7:123&#x2013;128</span></p>
<p style="top:601.9pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 56. Cahalane M, Demling RH: Early respiratory abnormalities from smoke </span></p>
<p style="top:610.9pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">inhalation. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">JAMA</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1984; 251:771&#x2013;773</span></p>
<p style="top:622.0pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 57. Miller K, Chang A: Acute inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Emerg Med Clin North Am</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:631.0pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2003; 21:533&#x2013;557</span></p>
<p style="top:642.0pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 58. Rabinowitz PM, Siegel MD: Acute inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Clin Chest Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:651.1pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2002; 23:707&#x2013;715</span></p>
<p style="top:662.1pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 59. Elamin E, Miller A: Impact of nebulized unfractionated heparin and </span></p>
<p style="top:671.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">N-acetylcysteine in management of smoke inhalation injury. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Crit Care</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> </span></p>
<p style="top:680.2pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">2009; 13(Suppl 1):P438</span></p>
<p style="top:691.2pt;left:300.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 60. Fuchs HJ, Borowitz DS, Christiansen DH, et al: Effect of aerosolized </span></p>
<p style="top:700.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">recombinant human DNase on exacerbations of respiratory symp-</span></p>
<p style="top:709.3pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">toms and on pulmonary function in patients with cystic fibrosis. The </span></p>
<p style="top:718.4pt;left:315.0pt;line-height:8.0pt"><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">Pulmozyme Study Group. </span><i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt">N Engl J Med</span></i><span style="font-family:AkzidenzGroteskBE,serif;font-size:8.0pt"> 1994; 331:637&#x2013;642</span></p>

</div>
